Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

83.79EUR
17 May 2013
Price Change (% chg)

€-1.01 (-1.19%)
Prev Close
€81.85
Open
€84.24
Day's High
€85.10
Day's Low
€83.64
Volume
4,501,891
Avg. Vol
2,339,771
52-wk High
€85.67
52-wk Low
€47.62

BAYGn.DE

Chart for BAYGn.DE

About

Bayer AG is a German management holding company with core competencies in the field of health care, nutrition and high-tech materials. It's business operations are organized into three subgroups: HealthCare, involved in the research, development and manufacture of health products for people and animals, CropScience, engaged in... (more)

Overall

Beta: 0.78
Market Cap (Mil.): €69,522.02
Shares Outstanding (Mil.): 826.95
Dividend: 1.90
Yield (%): 2.27

Financials

  BAYGn.DE Industry Sector
P/E (TTM): 27.11 35.66 35.83
EPS (TTM): 3.09 -- --
ROI: 6.59 19.36 18.72
ROE: 12.89 20.07 19.54
Search Stocks

Bayer to acquire herbal medicine maker Steigerwald

FRANKFURT, May 16 - Germany's largest drugmaker Bayer said it agreed to buy privately held Steigerwald Arzneimittelwerk GmbH, a maker of herbal treatments.

16 May 2013

Bayer, Algeta win FDA approval for prostate cancer drug

FRANKFURT, May 15 - German drugmaker Bayer and its development partner Algeta won approval from U.S. regulators for a prostate cancer drug that could eventually generate more than 1 billion euros ($1.31 billion) in annual sales.

15 May 2013

Bayer's plastics chief sees room to raise prices

LEVERKUSEN, Germany - Bayer suggested there was room to lift prices at its high-tech plastics and chemicals business this year to counter soaring raw material costs that squeezed first quarter margins.

10 May 2013

Court tells Bayer to compensate Schering shareholders

FRANKFURT, May 6 - A court ruled that Bayer did not pay some former Schering shareholders enough to acquire its German rival in 2007 and must now pay them more than 300 million euros ($392 million) in compensation, lawyers for the shareholders said.

06 May 2013

Bayer stops drug trial with haemophilia drug BAY 86-6150

FRANKFURT, May 3 - Bayer said its HealthCare division stopped a Phase II/III study testing its experimental treatment BAY 86-6150 on certain haemophilia A and B patients due to safety concerns.

03 May 2013

Bayer to buy birth-control devices maker for $1.1 billion

FRANKFURT - Germany's Bayer AG has agreed to buy U.S. contraceptive devices maker Conceptus for $1.1 billion, aiming to underpin its position as the world's largest women's healthcare provider,

29 Apr 2013

UPDATE 1-Bayer to buy birth-control devices maker for $1.1 bln

* Purchase of Concetpus is latest in string of bolt-on deals

29 Apr 2013

CORRECTED-Bayer plans to buy Conceptus for $1.1 bln

FRANKFURT, April 29 - Germany's Bayer agreed to acquire U.S. birth-control devices company Conceptus for $1.1 billion in cash, to cement its position as the world's largest women's healthcare provider.

29 Apr 2013

Bayer cuts plastics outlook, as higher costs hurt

FRANKFURT - Weak demand for Bayer's plastics and chemicals forced the diversified healthcare group to lower its outlook for its MaterialScience division, marring earnings gains at its farming pesticides unit.

25 Apr 2013

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$127.00
Provider: Wright Reports
$472.00
Provider: Finlabo SIM Spa
$58.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks